© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Corcept Therapeutics Incorporated (CORT) stock surged +0.72%, trading at $59.69 on NASDAQ, up from the previous close of $59.26. The stock opened at $59.46, fluctuating between $59.11 and $60.19 in the recent session.
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Employees | 352 |
Beta | 0.46 |
Sales or Revenue | $482.38M |
5Y Sales Change% | 1.33% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Corcept Therapeutics Incorporated (NASDAQ: CORT) stock price is $59.69 in the last trading session. During the trading session, CORT stock reached the peak price of $60.19 while $59.11 was the lowest point it dropped to. The percentage change in CORT stock occurred in the recent session was 0.72% while the dollar amount for the price change in CORT stock was $0.43.
The NASDAQ listed CORT is part of Biotechnology industry that operates in the broader Healthcare sector. Corcept Therapeutics Incorporated designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. William Guyer Pharm.D.
Chief Devel. Officer
Dr. Hazel Hunt Ph.D.
Chief Scientific Officer
Dr. Joseph K. Belanoff M.D.
Co-Founder, Pres, Chief Executive Officer & Director
Mr. Joseph Douglas Lyon
Chief Accounting Officer
Mr. Sean Maduck
Pres of Corcept Endocrinology
Ms. Amy Flood
Chief HR & Communications Officer
Mr. Atabak Mokari
Chief Financial Officer & Treasurer
Mr. Gary Charles Robb
Chief Bus. Officer & Sec.
CORT's closing price is 184.36% higher than its 52-week low of $20.84 where as its distance from 52-week high of $62.22 is -4.76%.
Number of CORT employees currently stands at 352.
Official Website of CORT is: https://www.corcept.com
CORT could be contacted at phone 650 327 3270 and can also be accessed through its website. CORT operates from 149 Commonwealth Drive, Menlo Park, CA 94025, United States.
CORT stock volume for the day was 27.13K shares. The average number of CORT shares traded daily for last 3 months was 1.02M.
The market value of CORT currently stands at $6.25B with its latest stock price at $59.69 and 104.78M of its shares outstanding.